Goldline Pharmaceutical IPO is a Book Built SME public issue introduced by Goldline Pharmaceutical Limited. Through this IPO, the company aims to strengthen its financial position and support future business expansion while enhancing its operational capabilities. The public issue consists entirely of a fresh issue of equity shares, allowing the company to utilise the proceeds for its planned business objectives.
Goldline Pharmaceutical Limited operates in the pharmaceutical sector and is engaged in the marketing, distribution, and sale of a diversified range of pharmaceutical formulations. The company focuses on supplying branded medicines across multiple therapeutic categories through an established network of distributors, healthcare professionals, hospitals, pharmacies, and stockists located across different regions of India.
Its product portfolio covers various therapeutic segments, including cardiology, diabetology, orthopaedics, gastroenterology, paediatrics, neurology, anti-infectives, pain management, critical care, vitamins, minerals, and nutritional supplements. By offering medicines across several healthcare segments, the company aims to serve a broad customer base while reducing dependence on any single product category.
Goldline Pharmaceutical places significant emphasis on expanding its product portfolio, strengthening customer relationships, improving brand visibility, and increasing market penetration. The company continues to introduce new pharmaceutical formulations based on changing healthcare requirements while maintaining product quality and regulatory compliance.
India’s pharmaceutical industry continues to witness steady growth because of increasing healthcare awareness, higher medical expenditure, expanding healthcare infrastructure, government healthcare initiatives, and rising demand for quality medicines. These factors create long-term growth opportunities for pharmaceutical companies that maintain diversified product offerings and efficient distribution networks.
The proceeds from the IPO are proposed to be utilised for the company’s business requirements, including strengthening working capital, supporting future expansion plans, and meeting general corporate purposes. Investors should evaluate the company’s financial performance, business model, valuation, competitive position, and future growth prospects before making an investment decision.
Goldline Pharmaceutical IPO Details
| IPO Details | Information |
|---|---|
| IPO Name | Goldline Pharmaceutical IPO |
| Company Name | Goldline Pharmaceutical Limited |
| IPO Type | Book Built Issue |
| IPO Category | SME IPO |
| Face Value | ₹10 Per Equity Share |
| Price Band | ₹41 to ₹43 Per Equity Share |
| Issue Size | ₹11.61 Crore |
| Fresh Issue | 27,00,000 Equity Shares |
| Offer for Sale | Nil |
| Total Shares Offered | 27,00,000 Equity Shares |
| IPO Open Date | 12 May 2026 |
| IPO Close Date | 14 May 2026 |
| Basis of Allotment | 15 May 2026 |
| Refund Initiation | 18 May 2026 |
| Shares Credited to Demat Account | 18 May 2026 |
| Listing Date | 19 May 2026 |
| Listing Exchange | BSE SME |
| Lot Size | 3,000 Equity Shares |
| Issue Type | Book Built Issue |
| Registrar | KFin Technologies Limited |
| Book Running Lead Manager | Cumulative Capital Private Limited |
| Market Maker | Giriraj Stock Broking Private Limited |
The Goldline Pharmaceutical IPO consists entirely of a fresh issue of equity shares. The funds raised through the public issue are intended to strengthen the company’s financial resources and support its planned business objectives.
Goldline Pharmaceutical IPO Dates
The important dates relating to the Goldline Pharmaceutical IPO are provided below. Investors should monitor these dates to track the subscription period, allotment process, refund schedule, and listing timeline.
| IPO Event | Date |
|---|---|
| IPO Opening Date | 12 May 2026 |
| IPO Closing Date | 14 May 2026 |
| Basis of Allotment | 15 May 2026 |
| Refund Initiation | 18 May 2026 |
| Shares Credited to Demat Account | 18 May 2026 |
| Listing Date | 19 May 2026 |
Successful applicants received their allotted shares in their demat accounts before the company’s shares commenced trading on the BSE SME platform.
Goldline Pharmaceutical IPO Reservation
The allocation of shares under the Goldline Pharmaceutical IPO was made in accordance with the applicable SME IPO regulations prescribed for different categories of investors.
| Investor Category | Reservation |
|---|---|
| Qualified Institutional Buyers (QIB) | Not More Than 50% |
| Non-Institutional Investors (NII) | Not Less Than 15% |
| Retail Individual Investors (RII) | Not Less Than 35% |
The final allotment under each category depended upon the number of valid applications received during the IPO subscription period.
Goldline Pharmaceutical IPO Lot Size
Applications for the Goldline Pharmaceutical IPO were required to be submitted in multiples of the prescribed lot size.
| Application | Shares | Amount |
|---|---|---|
| Retail Minimum | 1 Lot (3,000 Shares) | ₹1,29,000 |
| Retail Maximum | 2 Lots (6,000 Shares) | ₹2,58,000 |
| HNI Minimum | 3 Lots (9,000 Shares) | ₹3,87,000 |
The application amount has been calculated using the upper price band of ₹43 per equity share. Applicants were required to maintain sufficient funds in their bank accounts until completion of the allotment process.
About Goldline Pharmaceutical Limited
Goldline Pharmaceutical Limited is engaged in the marketing and distribution of pharmaceutical products across multiple therapeutic categories. The company focuses on making quality healthcare products available through an organised distribution network that serves healthcare professionals, hospitals, pharmacies, distributors, and stockists across different parts of India. Over the years, it has expanded its product portfolio and strengthened its market presence by introducing products that address a wide range of healthcare requirements.
The company markets pharmaceutical formulations covering several therapeutic segments, enabling it to cater to diverse medical needs. Its portfolio includes products for cardiology, diabetology, gastroenterology, orthopaedics, paediatrics, neurology, anti-infectives, pain management, vitamins, minerals, nutritional supplements, and other healthcare categories. This diversified portfolio helps the company serve a broad customer base while reducing dependence on a single therapeutic segment.
Goldline Pharmaceutical continues to focus on expanding its product offerings by identifying changing healthcare requirements and introducing new formulations. The company also works towards strengthening relationships with doctors, healthcare institutions, distributors, and retailers to improve product availability and market reach.
The Indian pharmaceutical sector continues to grow due to increasing healthcare awareness, improving medical infrastructure, rising disposable income, expanding health insurance coverage, and higher demand for quality medicines. These industry trends create long-term opportunities for pharmaceutical companies with diversified product portfolios and efficient distribution networks.
The company aims to strengthen its presence in existing markets while exploring opportunities to expand into new geographical regions. By focusing on customer relationships, product quality, operational efficiency, and portfolio expansion, Goldline Pharmaceutical seeks to achieve sustainable long-term business growth.
Goldline Pharmaceutical IPO Financial Information
Reviewing a company’s financial performance helps investors understand its revenue growth, profitability, and overall financial position. Examining these financial results over multiple years provides a clearer picture of business stability, operational efficiency, and future growth potential.
Goldline Pharmaceutical Financial Summary
| Particulars | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue from Operations | ₹19.85 Crore | ₹23.57 Crore | ₹28.06 Crore |
| Total Income | ₹19.85 Crore | ₹23.57 Crore | ₹28.06 Crore |
| EBITDA | ₹2.19 Crore | ₹4.30 Crore | ₹5.83 Crore |
| Profit After Tax (PAT) | ₹0.26 Crore | ₹1.80 Crore | ₹2.83 Crore |
| EBITDA Margin | 11.06% | 18.25% | 20.78% |
| PAT Margin | 1.29% | 7.66% | 10.09% |
Goldline Pharmaceutical Limited has reported steady business growth during the last three financial years. Revenue has increased consistently, while profitability has improved at a faster pace, reflecting better operating performance. The rise in EBITDA and net profit also indicates improved cost management and stronger earnings generation. Investors should assess these financial trends together with the company’s expansion strategy, valuation, and future business prospects before making an investment decision.
Goldline Pharmaceutical IPO Key Performance Indicators (KPIs)
Key Performance Indicators provide a snapshot of the company’s financial efficiency, profitability, capital utilisation, and leverage position. These ratios help investors compare the company’s performance with other businesses operating in the pharmaceutical industry.
| KPI | Value |
|---|---|
| Return on Equity (ROE) | 35.83% |
| Return on Capital Employed (ROCE) | 38.45% |
| EBITDA Margin | 20.78% |
| PAT Margin | 10.09% |
| Debt-to-Equity Ratio | 1.50 |
| Current Ratio | 1.98 |
| Interest Coverage Ratio | 3.24 |
| Net Capital Turnover Ratio | 2.42 |
The financial indicators suggest that the company has maintained healthy profitability while improving operational efficiency over the reported period. Return ratios indicate effective utilisation of shareholders’ funds and capital employed, whereas margin expansion reflects better earnings from business operations. Investors should consider these financial metrics along with industry conditions, competitive positioning, and long-term business strategy before evaluating the IPO.
Objects of the Goldline Pharmaceutical IPO
Goldline Pharmaceutical Limited plans to utilise the net proceeds from the IPO for the following purposes:
- Funding the company’s working capital requirements.
- Supporting business expansion and operational growth.
- Strengthening marketing and distribution activities.
- Meeting general corporate purposes.
The proposed utilisation of IPO proceeds is intended to improve the company’s operational capabilities, support future expansion plans, and strengthen its overall financial position. Investors should evaluate these objectives together with the company’s business strategy and financial performance before making an investment decision.
Goldline Pharmaceutical IPO GMP
The Grey Market Premium (GMP) represents the price at which IPO shares are traded in the unofficial market before they are listed on the stock exchange. Since these transactions take place outside the regulated market, GMP should be viewed only as an indicator of investor sentiment rather than a guaranteed measure of listing performance. Investors should always evaluate the company’s financial performance, valuation, business fundamentals, and future growth potential instead of making investment decisions solely on grey market activity.
Goldline Pharmaceutical IPO GMP
| Particular | Value |
|---|---|
| IPO Price Band | ₹41 to ₹43 Per Share |
| Last GMP Before Listing | ₹0 |
| Expected Listing Price | ₹43 Per Share |
| Expected Listing Gain | 0.00% |
Goldline Pharmaceutical IPO Subscription Status
The subscription status reflects the demand received from different categories of investors during the IPO bidding period. Higher subscription levels generally indicate stronger investor participation, although investors should also consider the company’s financial performance and valuation before making an investment decision.
Goldline Pharmaceutical IPO Subscription
| Investor Category | Subscription (Times) |
|---|---|
| Qualified Institutional Buyers (QIB) | 1.18x |
| Non-Institutional Investors (NII) | 6.74x |
| Retail Individual Investors (RII) | 11.62x |
| Total Subscription | 6.89x |
The IPO attracted participation from all investor categories, with the retail investor segment recording the highest subscription level during the bidding period.
Goldline Pharmaceutical IPO Review
Goldline Pharmaceutical Limited operates in the pharmaceutical industry by marketing a diversified portfolio of healthcare products across multiple therapeutic categories. The company’s business model focuses on expanding its product portfolio, strengthening its distribution network, and improving market reach through relationships with healthcare professionals, distributors, pharmacies, and hospitals.
The Indian pharmaceutical industry continues to benefit from rising healthcare awareness, increasing demand for quality medicines, expanding healthcare infrastructure, and higher healthcare expenditure. These industry trends provide favourable long-term opportunities for companies with diversified product offerings and established distribution capabilities.
Goldline Pharmaceutical has reported consistent improvement in revenue and profitability over recent financial years. The company also continues to focus on expanding its product range and strengthening its business operations, which may support future growth. The funds raised through the IPO are expected to enhance working capital and support planned business objectives.
However, investors should also evaluate potential business risks, including intense competition within the pharmaceutical sector, regulatory compliance requirements, pricing pressure, dependence on distribution channels, and changing market demand before making an investment decision.
Considering the company’s financial performance, business strategy, and industry outlook, the Goldline Pharmaceutical IPO may be suitable for investors seeking exposure to the pharmaceutical sector. A detailed assessment of valuation, financial strength, and long-term growth prospects is recommended before investing.
Goldline Pharmaceutical IPO Strengths
Goldline Pharmaceutical Limited has developed its business by expanding its pharmaceutical product portfolio, strengthening its distribution network, and focusing on operational growth. The following factors contribute to the company’s business strengths.
- Diversified Product Portfolio – The company markets pharmaceutical formulations across multiple therapeutic categories, allowing it to serve a broad customer base while reducing dependence on any single product segment.
- Established Distribution Network – Goldline Pharmaceutical supplies its products through distributors, stockists, pharmacies, hospitals, and healthcare professionals across different regions, helping improve product availability and market reach.
- Consistent Financial Growth – The company has reported growth in revenue and profitability during recent financial years, reflecting improvements in business operations and financial performance.
- Expanding Market Presence – The company continues to introduce new pharmaceutical products and strengthen its presence across existing and new markets to support long-term business growth.
- Experienced Management Team – The promoters and management possess experience in the pharmaceutical industry and continue to focus on business expansion, operational efficiency, and customer relationship management.
- Growing Healthcare Industry – Increasing healthcare awareness, expanding medical infrastructure, and rising demand for pharmaceutical products provide favourable growth opportunities for the company’s future business.
Goldline Pharmaceutical IPO Risk Factors
Like every pharmaceutical company, Goldline Pharmaceutical Limited is exposed to various operational, financial, and industry-related risks that investors should carefully evaluate before investing.
- Regulatory Compliance Risk – The pharmaceutical industry is subject to strict regulatory requirements. Any non-compliance with applicable laws or quality standards may affect business operations.
- Intense Industry Competition – The company competes with established pharmaceutical manufacturers and marketers, which may impact pricing, market share, and future business growth.
- Dependence on Distribution Network – Business performance depends on maintaining strong relationships with distributors, stockists, healthcare professionals, and other channel partners.
- Working Capital Requirement – The pharmaceutical business requires adequate working capital for inventory management, receivables, and day-to-day operations. Any shortage of working capital may affect business efficiency.
- Product Acceptance Risk – The success of newly introduced pharmaceutical products depends on market acceptance, prescribing trends, and customer demand.
- Economic and Industry Conditions – Changes in government policies, healthcare regulations, pricing controls, or overall economic conditions may influence the company’s financial performance and future growth prospects.
Goldline Pharmaceutical IPO Promoters
Goldline Pharmaceutical Limited is promoted by individuals who have contributed to the company’s growth and development since its early stages. The promoters are responsible for defining the company’s long-term vision, expanding its pharmaceutical portfolio, strengthening distribution channels, and supporting business expansion. Their experience in the pharmaceutical sector continues to guide the company’s strategic and operational decisions.
Goldline Pharmaceutical IPO Promoters Details
| Promoter | Designation |
|---|---|
| Amol Laxmikant Mujumdar | Promoter |
| Swapan Premprakash Khandelwal | Promoter |
Goldline Pharmaceutical IPO Management Team
The day-to-day operations of Goldline Pharmaceutical Limited are supervised by a management team with experience in business management, pharmaceutical operations, finance, compliance, and corporate governance. The team focuses on improving operational efficiency, expanding market reach, maintaining regulatory compliance, and achieving sustainable business growth.
| Name | Designation |
|---|---|
| Amol Laxmikant Mujumdar | Chairman & Managing Director |
| Swapan Premprakash Khandelwal | Whole-Time Director |
| Prashant Shrikrishna Karkare | Executive Director |
| Avinash Pandurang Ambulkar | Executive Director |
| Prashant Vithalrao Rahate | Non-Executive Director |
| Mehul Hari Ranade | Independent Director |
| Renuka Saurabh Borole | Independent Director |
| Shraddha Kiran Kulkarni | Independent Director |
| Dipti Sharad Bhusari | Chief Financial Officer |
| Ruchi Sanket Modi | Company Secretary & Compliance Officer |
Goldline Pharmaceutical IPO Registrar Details
The registrar is responsible for handling the IPO application process, preparing the basis of allotment, processing refunds where applicable, transferring allotted shares to investors’ demat accounts, and responding to investor-related queries throughout the public issue process.
| Particular | Details |
|---|---|
| Registrar Name | KFin Technologies Limited |
| Website | www.kfintech.com |
| IPO Allotment Status | https://ris.kfintech.com/ipostatus |
| Email ID | [email protected] |
| Contact Number | +91-40-6716 2222 |
Goldline Pharmaceutical IPO Lead Manager Details
The Book Running Lead Manager is responsible for managing the IPO process, coordinating with regulatory authorities, overseeing issue-related activities, and ensuring compliance with applicable regulations from the opening of the issue until listing.
| Particular | Details |
|---|---|
| Lead Manager | Cumulative Capital Private Limited |
| Website | www.cumulativecapital.group |
| Email ID | [email protected] |
| Contact Number | +91-79-4009 9900 |
Goldline Pharmaceutical Limited Contact Details
| Particular | Details |
|---|---|
| Company Name | Goldline Pharmaceutical Limited |
| Registered Office | 103, F-1, Leela Apartment, Shilpa Housing Society, Near Saptagiri Nagar, Shanidham, Narendra Nagar, Nagpur – 440015, Maharashtra, India |
| Website | www.goldlinepharma.in |
| Email ID | [email protected] |
| Contact Number | +91-712-2786666 |
How to Check Goldline Pharmaceutical IPO Allotment Status
After the basis of allotment has been finalised, investors can verify whether they have received shares by using the online allotment facility provided by the registrar or the stock exchange.
Check Through KFin Technologies
- Open the KFin Technologies IPO allotment portal.
- Select Goldline Pharmaceutical IPO from the available list.
- Choose any one of the available search methods such as PAN Number, Application Number, or DP/Client ID.
- Enter the required details carefully.
- Click Submit to view your allotment result.
Check Through BSE
- Visit the official BSE IPO allotment page.
- Select Goldline Pharmaceutical IPO from the list.
- Enter your PAN Number or Application Number.
- Complete the verification process.
- Click Search to view the allotment status.
Goldline Pharmaceutical IPO Listing Performance
Goldline Pharmaceutical Limited was listed on the BSE SME platform after completing its IPO process. The listing performance gives investors an overview of how the market responded to the public issue on the first day of trading. Although listing gains are often closely watched, long-term investment decisions should primarily be based on the company’s financial performance, business model, and future growth prospects.
| Particular | Details |
|---|---|
| Listing Exchange | BSE SME |
| Listing Date | 19 May 2026 |
| Issue Price | ₹43 Per Share |
| Listing Price | ₹43.00 Per Share |
| Listing Gain | 0.00% |
| Listing Gain (%) | 0.00% |
The shares were listed at the issue price, resulting in a flat market debut without any listing premium.
Should You Invest in Goldline Pharmaceutical IPO?
Goldline Pharmaceutical Limited operates in the pharmaceutical sector by marketing a diversified portfolio of healthcare products across various therapeutic categories. The company has built its business around expanding its product portfolio, strengthening its distribution network, and increasing its presence across different healthcare markets.
Over the years, the company has reported growth in revenue and profitability while continuing to expand its pharmaceutical product offerings. Its business strategy focuses on improving operational efficiency, strengthening relationships with distributors and healthcare professionals, and increasing market penetration through continuous business development initiatives.
The Indian pharmaceutical industry continues to benefit from favourable long-term trends, including increasing healthcare awareness, growing healthcare expenditure, improved medical infrastructure, and rising demand for quality medicines. These factors provide opportunities for pharmaceutical companies with diversified products and established marketing capabilities.
At the same time, investors should carefully consider factors such as regulatory compliance, competition within the pharmaceutical industry, working capital requirements, product acceptance, and overall market conditions before investing.
Investors with a long-term investment approach should analyse the company’s financial statements, valuation, future expansion strategy, industry outlook, and overall business fundamentals before making an investment decision.
Conclusion
Goldline Pharmaceutical Limited has established its presence in the pharmaceutical industry by offering a diversified range of healthcare products across multiple therapeutic segments. The company continues to focus on expanding its product portfolio, strengthening its distribution network, and improving operational efficiency to support long-term business growth.
The pharmaceutical sector in India continues to offer significant growth opportunities because of increasing healthcare awareness, rising demand for medicines, improving medical infrastructure, and expanding healthcare services. These industry trends create a favourable environment for companies that maintain diversified product portfolios and efficient distribution systems.
The funds raised through the IPO are expected to support the company’s business operations and strengthen its financial position. However, investors should also evaluate industry competition, regulatory requirements, working capital needs, financial performance, valuation, and long-term business strategy before making an investment decision.
Overall, the Goldline Pharmaceutical IPO provides an opportunity to invest in a company operating in India’s growing pharmaceutical industry. A detailed assessment of the company’s financial strength, operational performance, growth strategy, and future prospects can help investors make informed investment decisions aligned with their investment objectives.
Frequently Asked Questions (FAQs)
What is the Goldline Pharmaceutical IPO?
Goldline Pharmaceutical IPO is a Book Built SME public issue by Goldline Pharmaceutical Limited comprising a fresh issue of equity shares.
What was the Goldline Pharmaceutical IPO price band?
The IPO was offered at a price band of ₹41 to ₹43 per equity share.
What was the issue size of the Goldline Pharmaceutical IPO?
The total issue size of the IPO was ₹11.61 crore.
When did the Goldline Pharmaceutical IPO open and close?
The IPO opened on 12 May 2026 and closed on 14 May 2026.
What was the lot size of the Goldline Pharmaceutical IPO?
The minimum application size was 1 lot consisting of 3,000 equity shares.
Who was the registrar for the Goldline Pharmaceutical IPO?
KFin Technologies Limited acted as the registrar to the issue.
Who was the lead manager for the Goldline Pharmaceutical IPO?
Cumulative Capital Private Limited was the Book Running Lead Manager for the public issue.
Where are Goldline Pharmaceutical shares listed?
The company’s equity shares are listed on the BSE SME platform.
What does Goldline Pharmaceutical Limited do?
Goldline Pharmaceutical Limited is engaged in the marketing and distribution of pharmaceutical formulations across multiple therapeutic categories, serving healthcare professionals and distribution partners across India.
What were the objectives of the Goldline Pharmaceutical IPO?
The IPO proceeds were proposed to be utilised for meeting working capital requirements and general corporate purposes, along with supporting the company’s future business growth plans.
